Switching Between GLP-1 Medications

People switch for five reasons: it stopped working, the side effects were intolerable, supply failed, insurance changed, or cost. Only the first two are clinical, and all five end up in the same conversation.

First: which kind of switch is this?

These are not the same problem and they get conflated constantly.

Same molecule, different brand — Ozempic to Wegovy, or Mounjaro to Zepbound. This is straightforward. The molecule is identical; the products differ in licensed indication, available doses and device. Your prescriber maps your current dose onto the nearest available dose of the new product, and tolerability usually carries across. The main practical difference to know is that the missed-dose windows differ between Ozempic and Wegovy despite the identical molecule.

Different molecule — semaglutide to tirzepatide, or back. This is a genuine restart, and the rest of this article is about it.

There is no conversion table

This is the thing people most want and it does not exist.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts at both the GIP and GLP-1 receptors. They are different molecules with different potencies, different dose ranges, and different titration schedules. No regulator or manufacturer publishes an equivalence table, and the head-to-head evidence — SURPASS-2 compared specific dose pairs in type 2 diabetes — tells you how those particular doses performed against each other, not how to convert an arbitrary dose of one into the other.

Any chart you find online mapping “1 mg semaglutide = X mg tirzepatide” is somebody’s estimate. Treat it as such.

So you re-titrate

The practical consequence: you start the new drug near the bottom of its own schedule and climb. Not at a notionally equivalent dose.

The reason is tolerability rather than efficacy. Titration schedules exist because the gastrointestinal adaptation builds gradually over weeks, and that adaptation is at least partly molecule-specific — tolerating 2.4 mg of semaglutide does not mean you will tolerate 10 mg of tirzepatide. Starting high is the switching mistake, and it produces a fortnight bad enough that people abandon a drug that would have suited them.

Some prescribers start one step above the lowest dose in someone who was comfortable at a high dose of the previous drug. That is a reasonable clinical judgement and it is theirs to make, not something to do unilaterally.

Budget two to three months to get back to a comparable level of effect. That is the real cost of switching and it is worth weighing before you decide.

Timing the gap

Both molecules have a half-life of roughly a week. That has two consequences.

A week is usually enough. The common approach is to take the first dose of the new drug on what would have been your next injection day. You do not need a long washout, because a long washout mostly buys you returning appetite with no compensating benefit.

They overlap regardless. After one week, roughly half the previous drug is still present; it takes about 4–5 weeks to clear substantially. So for the first month you are, pharmacologically, on a bit of both. That is expected and it is part of why the first weeks on the new drug can feel unrepresentative. The arithmetic is in how long these drugs stay in your system.

If you have type 2 diabetes, the gap matters more, because glycemic control should not be allowed to drift. That is a conversation with your prescriber about monitoring during the transition, not a scheduling decision.

What to expect in the first month

The dip in weeks one to three is normal and it is where people conclude the new drug is not working. It is too early to conclude anything. Judge a switch at 12 weeks, not at 3.

Before you switch for non-response

If the reason is that you have plateaued, do the checks first — because a switch resets your titration and costs you a quarter of a year.

Confirm it is a genuine plateau rather than intake drift or recomposition the scale cannot see, and confirm you have used the dose headroom available on your current drug. Why you stopped losing weight covers how to tell the difference.

If you are at maximum dose, adherent, training, tracking honestly, and 12 weeks have produced nothing — then switching is a reasonable next move, and the individual variation in response is real. I have had patients plateau at 6% on one agent and lose 18% on the other. There is currently no way to predict who they are, which is the honest position set out in semaglutide versus tirzepatide.

Switching for side effects

Different logic, and often a better-founded reason.

Before switching molecules, the higher-yield move is usually slowing the titration on the drug you are on — holding a dose for an extra 4–8 weeks rather than stepping up on schedule. That resolves a large share of tolerability problems and costs nothing.

If the problem is specific and persistent — intractable nausea, severe constipation, reflux that has not settled after months at a stable dose — then switching is reasonable, and side-effect profiles do differ between people even where they look similar in aggregate. The drug-by-drug detail is in the side-effects hub.

What switching does not solve is a red-flag event. If you stopped because of suspected pancreatitis, gallbladder disease, or a severe allergic reaction, whether to try another agent in the same class is a specialist decision and not a matter of picking a different brand.

The practical checklist

• Confirm which kind of switch this is
• Agree the starting dose with your prescriber — expect near the bottom
• Time the first new dose to your usual injection day, about a week after the last old one
• Expect appetite to return for 1–3 weeks
• Do not judge it before 12 weeks
• Keep protein and training constant through the transition, since the ramp-up period is exactly when lean mass is least defended
• Check the new product’s missed-dose window; it may not match the old one